Literature DB >> 23401589

Long-term antibody memory induced by synthetic peptide vaccination is protective against Streptococcus pyogenes infection and is independent of memory T cell help.

Manisha Pandey1, Michelle N Wykes, Jon Hartas, Michael F Good, Michael R Batzloff.   

Abstract

Streptococcus pyogenes (group A Streptococcus [GAS]) is a leading human pathogen associated with a diverse array of mucosal and systemic infections. Vaccination with J8, a conserved region synthetic peptide derived from the M-protein of GAS and containing only 12 aa from GAS, when conjugated to diphtheria toxoid, has been shown to protect mice against a lethal GAS challenge. Protection has been previously shown to be Ab-mediated. J8 does not contain a dominant GAS-specific T cell epitope. The current study examined long-term Ab memory and dissected the role of B and T cells. Our results demonstrated that vaccination generates specific memory B cells (MBC) and long-lasting Ab responses. The MBC response can be activated following boost with Ag or limiting numbers of whole bacteria. We further show that these memory responses protect against systemic infection with GAS. T cell help is required for activation of MBC but can be provided by naive T cells responding directly to GAS at the time of infection. Thus, individuals whose T cells do not recognize the short synthetic peptide in the vaccine will be able to generate a protective and rapid memory Ab response at the time of infection. These studies significantly strengthen previous findings, which showed that protection by the J8-diphtheria toxoid vaccine is Ab-mediated and suggest that in vaccine design for other organisms the source of T cell help for Ab responses need not be limited to sequences from the organism itself.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23401589      PMCID: PMC3594626          DOI: 10.4049/jimmunol.1202333

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  42 in total

1.  Unique requirements for reactivation of virus-specific memory B lymphocytes.

Authors:  Florian J Weisel; Uwe K Appelt; Andrea M Schneider; Jasmin U Horlitz; Nico van Rooijen; Heinrich Korner; Michael Mach; Thomas H Winkler
Journal:  J Immunol       Date:  2010-08-25       Impact factor: 5.422

2.  Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine.

Authors:  Grazia Galli; Kathy Hancock; Katja Hoschler; Joshua DeVos; Michaela Praus; Monia Bardelli; Carmine Malzone; Flora Castellino; Chiara Gentile; Teresa McNally; Giuseppe Del Giudice; Angelika Banzhoff; Volker Brauer; Emanuele Montomoli; Maria Zambon; Jacqueline Katz; Karl Nicholson; Iain Stephenson
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-27       Impact factor: 11.205

Review 3.  Group A streptococcal vaccines: facts versus fantasy.

Authors:  Andrew C Steer; Michael R Batzloff; Kim Mulholland; Jonathan R Carapetis
Journal:  Curr Opin Infect Dis       Date:  2009-12       Impact factor: 4.915

4.  Correlation between bioluminescence and bacterial burden in passively protected mice challenged with a recombinant bioluminescent M49 group A streptococcus Strain.

Authors:  Meru Sheel; Manisha Pandey; Michael F Good; Michael R Batzloff
Journal:  Clin Vaccine Immunol       Date:  2009-11-04

5.  EdU incorporation is an alternative non-radioactive assay to [(3)H]thymidine uptake for in vitro measurement of mice T-cell proliferations.

Authors:  Yongmao Yu; Alka Arora; Weixian Min; Chaim M Roifman; Eyal Grunebaum
Journal:  J Immunol Methods       Date:  2009-07-30       Impact factor: 2.303

6.  Protection from CMV infection in immunodeficient hosts by adoptive transfer of memory B cells.

Authors:  Karin Klenovsek; Florian Weisel; Andrea Schneider; Uwe Appelt; Stipan Jonjic; Martin Messerle; Birgit Bradel-Tretheway; Thomas H Winkler; Michael Mach
Journal:  Blood       Date:  2007-07-26       Impact factor: 22.113

7.  Antigen-specific memory B-cell responses to Vibrio cholerae O1 infection in Bangladesh.

Authors:  Aaron M Harris; M Saruar Bhuiyan; Fahima Chowdhury; Ashraful I Khan; Azim Hossain; Emily A Kendall; Atiqur Rahman; Regina C LaRocque; Jens Wrammert; Edward T Ryan; Firdausi Qadri; Stephen B Calderwood; Jason B Harris
Journal:  Infect Immun       Date:  2009-06-15       Impact factor: 3.441

8.  The magnitude of the antibody and memory B cell responses during priming with a protein-polysaccharide conjugate vaccine in human infants is associated with the persistence of antibody and the intensity of booster response.

Authors:  Geraldine Blanchard Rohner; Matthew D Snape; Dominic F Kelly; Tessa John; Anita Morant; Ly-Mee Yu; Astrid Borkowski; Francesca Ceddia; Ray Borrow; Claire-Anne Siegrist; Andrew J Pollard
Journal:  J Immunol       Date:  2008-02-15       Impact factor: 5.422

9.  T-cell epitope polymorphisms of the Plasmodium falciparum circumsporozoite protein among field isolates from Sierra Leone: age-dependent haplotype distribution?

Authors:  Amadu Jalloh; Muctarr Jalloh; Hiroyuki Matsuoka
Journal:  Malar J       Date:  2009-06-05       Impact factor: 2.979

10.  Mechanism of protection induced by group A Streptococcus vaccine candidate J8-DT: contribution of B and T-cells towards protection.

Authors:  Manisha Pandey; Michael R Batzloff; Michael F Good
Journal:  PLoS One       Date:  2009-04-02       Impact factor: 3.240

View more
  22 in total

Review 1.  Strategies in the development of vaccines to prevent infections with group A streptococcus.

Authors:  Michael F Good; Michael R Batzloff; Manisha Pandey
Journal:  Hum Vaccin Immunother       Date:  2013-06-28       Impact factor: 3.452

2.  Investigation of group A Streptococcus immune responses in an endemic setting, with a particular focus on J8.

Authors:  Patricia Therese Campbell; Hannah Frost; Pierre R Smeesters; Joseph Kado; Michael F Good; Michael Batzloff; Nicholas Geard; Jodie McVernon; Andrew Steer
Journal:  Vaccine       Date:  2018-11-03       Impact factor: 3.641

3.  Host Pathways of Hemostasis that Regulate Group A Streptococcus pyogenes Pathogenicity.

Authors:  Victoria A Ploplis; Francis J Castellino
Journal:  Curr Drug Targets       Date:  2020       Impact factor: 3.465

4.  Peptide amphiphile micelles self-adjuvant group A streptococcal vaccination.

Authors:  Amanda Trent; Bret D Ulery; Matthew J Black; John C Barrett; Simon Liang; Yulia Kostenko; Natalie A David; Matthew V Tirrell
Journal:  AAPS J       Date:  2014-12-20       Impact factor: 4.009

5.  M-protein based vaccine induces immunogenicity and protection from Streptococcus pyogenes when delivered on a high-density microarray patch (HD-MAP).

Authors:  Jamie-Lee S Mills; Cesar M Jayashi Flores; Manisha Pandey; Michael F Good; Simone Reynolds; Christine Wun; Ainslie Calcutt; S Ben Baker; Senthil Murugappan; Alexandra C I Depelsenaire; Jessica Dooley; Paul V Fahey; Angus H Forster
Journal:  NPJ Vaccines       Date:  2020-08-07       Impact factor: 7.344

6.  A systematic and functional classification of Streptococcus pyogenes that serves as a new tool for molecular typing and vaccine development.

Authors:  Martina Sanderson-Smith; David M P De Oliveira; Julien Guglielmini; David J McMillan; Therese Vu; Jessica K Holien; Anna Henningham; Andrew C Steer; Debra E Bessen; James B Dale; Nigel Curtis; Bernard W Beall; Mark J Walker; Michael W Parker; Jonathan R Carapetis; Laurence Van Melderen; Kadaba S Sriprakash; Pierre R Smeesters
Journal:  J Infect Dis       Date:  2014-05-05       Impact factor: 5.226

7.  The contribution of non-human primate models to the development of human vaccines.

Authors:  Tania Rivera-Hernandez; Diane G Carnathan; Peter M Moyle; Istvan Toth; Nicholas P West; Paul R Young; Guido Silvestri; Mark J Walker
Journal:  Discov Med       Date:  2014-12       Impact factor: 2.970

Review 8.  Disease manifestations and pathogenic mechanisms of Group A Streptococcus.

Authors:  Mark J Walker; Timothy C Barnett; Jason D McArthur; Jason N Cole; Christine M Gillen; Anna Henningham; K S Sriprakash; Martina L Sanderson-Smith; Victor Nizet
Journal:  Clin Microbiol Rev       Date:  2014-04       Impact factor: 26.132

Review 9.  Correlates of Protection for M Protein-Based Vaccines against Group A Streptococcus.

Authors:  Shu Ki Tsoi; Pierre R Smeesters; Hannah R C Frost; Paul Licciardi; Andrew C Steer
Journal:  J Immunol Res       Date:  2015-05-25       Impact factor: 4.818

10.  Extensive diversity of Streptococcus pyogenes in a remote human population reflects global-scale transmission rather than localised diversification.

Authors:  Rebecca J Towers; Jonathan R Carapetis; Bart J Currie; Mark R Davies; Mark J Walker; Gordon Dougan; Philip M Giffard
Journal:  PLoS One       Date:  2013-09-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.